FY2019 Earnings Estimate for Allergan plc (NYSE:AGN) Issued By Cantor Fitzgerald
Allergan plc (NYSE:AGN) – Equities research analysts at Cantor Fitzgerald lowered their FY2019 EPS estimates for Allergan in a report issued on Sunday, November 10th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings of $16.60 per share for the year, down from their previous forecast of $16.62. Cantor Fitzgerald has a “Neutral” rating and a $165.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Allergan’s FY2020 earnings at $15.67 EPS.
AGN has been the subject of a number of other research reports. ValuEngine lowered shares of Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. Svb Leerink reissued a “market perform” rating and issued a $188.00 price objective (down previously from $217.00) on shares of Allergan in a report on Thursday, July 18th. Sanford C. Bernstein lowered shares of Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price objective for the company. in a report on Tuesday, July 16th. Royal Bank of Canada reissued a “hold” rating and issued a $178.00 price objective on shares of Allergan in a report on Thursday, August 8th. Finally, UBS Group upped their price objective on shares of Allergan from $172.00 to $189.00 and gave the company a “buy” rating in a report on Thursday, September 12th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $175.16.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, November 5th. The company reported $4.25 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $4.25. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $3.88 billion. During the same quarter in the prior year, the firm earned $4.25 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year.
A number of large investors have recently modified their holdings of the stock. Haverford Trust Co. grew its holdings in shares of Allergan by 14.6% during the 2nd quarter. Haverford Trust Co. now owns 4,438 shares of the company’s stock worth $743,000 after purchasing an additional 565 shares during the period. Alps Advisors Inc. lifted its holdings in Allergan by 4.4% during the second quarter. Alps Advisors Inc. now owns 6,938 shares of the company’s stock worth $1,162,000 after acquiring an additional 292 shares in the last quarter. Fulton Bank N.A. lifted its holdings in Allergan by 19.9% during the second quarter. Fulton Bank N.A. now owns 14,220 shares of the company’s stock worth $2,381,000 after acquiring an additional 2,360 shares in the last quarter. Rational Advisors LLC lifted its holdings in Allergan by 650.0% during the second quarter. Rational Advisors LLC now owns 285 shares of the company’s stock worth $48,000 after acquiring an additional 247 shares in the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in Allergan by 1.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 93,208 shares of the company’s stock worth $15,686,000 after acquiring an additional 900 shares in the last quarter. 80.64% of the stock is currently owned by hedge funds and other institutional investors.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Wednesday, November 13th will be issued a $0.74 dividend. The ex-dividend date of this dividend is Tuesday, November 12th. This represents a $2.96 annualized dividend and a yield of 1.63%. Allergan’s dividend payout ratio (DPR) is 17.74%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Article: How does a security become overbought?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.